Pancreatic, thyroid, and other endocrine cancers:
Indications for: THYROGEN
Adjunctive diagnostic tool for serum thyroglobin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy. Adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer.
Adult Dosage:
Give by IM inj into the buttock. 0.9mg, followed by a second 0.9mg injection 24 hours later. For radioiodine imaging or remnant ablation, give radioiodine 24 hours after the second Thyrogen injection.
Children Dosage:
Not established.
THYROGEN Warnings/Precautions:
See full labeling. Reports of death in patients who are non-thyroidectomized or with distant metastatic thyroid cancer wthin 24hrs after administration. Heart disease, metastatic disease: increased risk of Thyrogen-induced hyperthyroidism, consider hospitalization for administration and post-administration observation. Caution patients regarding possible neurologic symptoms. Consider pretreatment with glucocorticoids in those whose tumor expansion may compromise vital anatomic structures (eg, trachea, lung metastases). Anti-thyroglobulin (Tg) antibodies may render Tg levels uninterpretable; consider further evaluation with thyroid hormone withdrawal scan. Residual thyroid tissue. End-stage renal disease. Elderly. Pregnancy, nursing mothers: contraindicated if concomitant with radioiodine.
THYROGEN Classification:
Thyroid stimulating hormone (recombinant).
Adverse Reactions:
Nausea, headache, fatigue, influenza-like symptoms; death (in non-thyroidectomized or with distant metastatic thyroid cancer), stroke and other neurologic events, sudden rapid tumor enlargement in distant metastatic thyroid cancer.
Drug Elimination:
Renal.
Generic Drug Availability:
NO
How Supplied:
Single-dose vials—2
